Global Antibiotics Partnering Terms and Agreements 2010 to 2016

Publisher Name :
Date: 01-Oct-2016
No. of pages: 222
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in antibiotics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Antibiotics partnering contract documents

Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

Antibiotics

Aminoglycosides

Cephalosporin

Clindamycin

Macrolides

Penicillin

Quinolones

Sulfonamides

Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 includes:

Trends in antibiotics dealmaking in the biopharma industry since 2010

Analysis of antibiotics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life antibiotics deals

Access to over 200 antibiotics deal records and contract documents where available

The leading antibody deals by value since 2010

Most active antibiotics dealmakers since 2010

The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of antibiotics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of antibiotics agreements with numerous real life case studies

Comprehensive access to over 200 antibiotics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available

Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus

Identify leading antibiotics deals by value since 2010

Identify the most active antibiotics dealmakers since 2010

Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies

Insight into the terms included in a antibiotics agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Antibiotics Partnering Terms and Agreements 2010 to 2016

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals -Feb 03 2014
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical- July 01 2013
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

Chapter 3 - Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers
4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory
5.1. Introduction
5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type
Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Metronidazole
Penicillin
Quinolones
Tetracycline

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Antibiotics deals by company A-Z
Appendix 2 - Antibiotics deals by stage of development
Appendix 3 - Antibiotics deals by deal type
Appendix 4 - Antibiotics deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering


List of Figures

Figure 1: Antibiotics partnering since 2010
Figure 2: Active antibiotics dealmaking activity- 2010 to 2016
Figure 3: Antibiotics partnering by deal type since 2010
Figure 4: Antibiotics partnering by disease type since 2010
Figure 5: Antibiotics partnering by industry sector since 2010
Figure 6: Antibiotics deals with a headline value
Figure 7: Antibiotics deals with an upfront value
Figure 8: Antibiotics deals with a milestone value
Figure 9: Antibiotics deals with a royalty rate value
Figure 10: Top antibiotics deals by value since 2010
Figure 11: Most active antibiotics dealmakers 2010 to 2016
Figure 12: Antibiotics partnering by technology type since 2010
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Impetigo - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 45
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2016, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabet......
  • Q Fever - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 41
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2016, provides an overview of the Q Fever (Infectious Disease) pipeline landscape.Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscle pain. Risk factors include occupations. Treatment includes antibiotics.......
  • Global Niclosamide Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 102
    Notes: Production, means the output of Niclosamide Revenue, means the sales value of Niclosamide This report studies Niclosamide in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Shanxi Hanjiang Pharmaceutical - Anhui Topsun Pharmaceutical - Zhengqing Pharmaceutical Group......
  • Global Meningococcal Infections Vaccine Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 100
    Notes: Production, means the output of Meningococcal Infections Vaccine Revenue, means the sales value of Meningococcal Infections Vaccine This report studies Meningococcal Infections Vaccine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Sanofi-Pasteur - Beijing Tiantan Biologi......
  • United States Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 100
    Notes: Sales, means the sales volume of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Revenue, means the sales value of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections This report studies sales (consumption) of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Pfizer - Merck - Astra......
  • Escherichia coli Infections - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 165
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 177
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The pr......
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 191
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness......
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 273
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pai......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs